Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × navitoclax × 1 year × Clear all
NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04472598 2026-03-23

TRANSFORM-1

AbbVie

Phase 3 Completed
252 enrolled 17 charts
Myeloid

Neoplasms, Primary Myelofibrosis

NCT05192889 2025-09-22

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

St. Jude Children's Research Hospital

Phase 1/2 Active not recruiting
35 enrolled 12 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡